Tempus AI (TEM) Company Report

Tempus AI reported $1.27 billion in revenue last year, surpassing guidance, with its core business growing approximately 30% and the data business accelerating to 68% growth in Q4 (excluding a one-time warrant).
The company forecasts 25% growth over the next three years, with a target of $1.59 billion in revenue and $65 million in adjusted EBITDA for the current year (2026).
The data business achieved $316 million in revenue last year, growing 30%, and holds over $1.1 billion in total contract value (TCV), of which $350 million is non-cancelable and attributed to 2026.
Diagnostic average selling prices (ASPs) are projected to increase from $1,630 to approximately $2,200 over the coming years, driven by enhanced reimbursement from FDA approvals and expanding commercial coverage.
Tempus is heavily investing in AI, developing large multimodal foundation models for oncology in collaboration with AstraZeneca and Pathos, utilizing substantial compute infrastructure.

7 days ago

Transcript

Tempus reports strong financial performance and provides 2026 revenue guidance

TEM

Guidance Update

Revenue Acceleration/Inflection

New Projects/Investments

Tempus reported $1.27 billion in total revenue last year, exceeding guidance, with its core business growing at approximately 30%.
The company's data business generated $316 million in revenue last year, growing at 30%, and demonstrated 68% growth in Q4 (excluding a one-time AZ warrant in Q4 2025).
Tempus has secured over $1.1 billion in total contract value (TCV) for data licenses, including $350 million related to 2026, and achieved a net revenue retention of 126% in its data business.
For the current year, Tempus projects $1.59 billion in revenue, representing 25% growth, and expects to generate $65 million in adjusted EBITDA.
The company is now self-sustaining and generates positive adjusted EBITDA, underpinned by a unique data set of 45 million patients and 400 petabytes of multimodal healthcare data.

7 days ago

Transcript

Tempus AI Provides Business Update and Financial Guidance

TEM

Guidance Update

Revenue Acceleration/Inflection

New Projects/Investments

**Tempus AI reported strong financial results for 2025, with total revenue reaching $1.27 billion, exceeding guidance, and projects approximately $1.59 billion for 2026, driven by a 25% growth rate over the next three years. **
**The data business demonstrated significant momentum, achieving $316 million in revenue last year with 31% growth, and 68% growth in Q4 2025 (excluding a one-time warrant). ** It boasts over $1.1 billion in total contract value (TCV), with $350 million allocated for 2026, and a net revenue retention of 126%.
**The diagnostics business also performed well, with average selling prices (ASPs) expected to increase from $1,630 to $2,200 over several years due to enhanced reimbursement. **
**Tempus AI is self-sustaining and generates positive adjusted EBITDA, with an expected $65 million for 2026, while continuing to invest heavily in its AI-driven platform and data sets. **

7 days ago

Transcript

Tempus Provides Q4 2025 Results Preview and 2026 Outlook

TEM

Earnings

Guidance Update

M&A

Tempus expects ~$1.27 billion in revenue for 2025, an ~83% year-over-year increase.
For Q4 2025, the company anticipates ~121% revenue growth in Diagnostics and ~25% revenue growth in Data & Applications year-over-year.
Tempus projects ~$1.59 billion in revenue for 2026, representing ~25% year-over-year growth, and expects ~$65 million in Adjusted EBITDA for the year.
In 2025, Tempus expanded into rare disease and digital pathology, which included the Ambry acquisition in February 2025.

7 days ago

Presentation

Tempus AI Reports Record Total Contract Value and Preliminary 2025 Financials

TEM

Earnings

Revenue Acceleration/Inflection

Guidance Update

Tempus AI announced a record Total Contract Value (TCV) exceeding $1.1 billion as of December 31, 2025.
The company reported preliminary, unaudited Data and application revenue of ~$316 million for the full year 2025, representing approximately 31% year-over-year growth, with Insights (data licensing) growing 38%.
Tempus achieved net revenue retention of ~126% in 2025 and signed data agreements with over 70 customers, including major pharmaceutical companies.
These 2025 financial estimates are preliminary and unaudited and are subject to change, with complete results anticipated in February 2026.

8 days ago

Press Release

Tempus AI Announces Preliminary Q4 and Full Year 2025 Results

TEM

Earnings

Revenue Acceleration/Inflection

Tempus AI announced preliminary, unaudited results for the fourth quarter and full year ended December 31, 2025, with key financial highlights as follows :

Metric	FY 2025	Q4 2025
Revenue ($USD Millions)	$1,270	$367
Revenue Growth (YoY)	83%	83%
Diagnostics Revenue ($USD Millions)	$955	$266
Diagnostics Revenue Growth (YoY)	111%	121%
Data and Applications Revenue ($USD Millions)	$316	$100
Data and Applications Revenue Growth (YoY)	31%	25%

CEO Eric Lefkofsky characterized 2025 as an "exceptional year", highlighting that both product lines surpassed initial expectations and are experiencing accelerating growth, which positions the company strongly for 2026 with AI as a catalyst.
It is important to note that these results are preliminary and unaudited, and the final financial results for these periods are anticipated to be reported in February 2026.

8 days ago

Press Release

Tempus AI Achieves Positive Adjusted EBITDA in Q3 and Outlines Growth and Profitability Strategy

TEM

Earnings

New Projects/Investments

Guidance Update

Tempus AI achieved its first positive Adjusted EBITDA in Q3. The company plans to reinvest two-thirds of incremental gross profit dollars back into the business, with one-third dropping to Adjusted EBITDA, assuming approximately 25% annual top-line growth over the next three years.
The Ambry acquisition, closed in February of this year, strategically expands Tempus AI's reach to earlier-stage cancer patients and into rare and undiagnosed disorders. Ambry was already EBITDA positive, supporting Tempus AI's profitability goals.
Tempus AI secured a $200 million data license deal with AstraZeneca and Pathos AI, which will be largely recognized ratably over the next three years. This follows a previous $320 million deal with AstraZeneca in 2021.
The launch of xT CDx, a solid tumor DNA test with FDA approval and ADLT status, carries a $4,500 Medicare reimbursement. By the end of Q3, approximately 30% of solid tumor DNA testing volume had migrated to this version, with plans to migrate the vast majority of the remaining 70% in 2026.
Tempus AI's data business is built on connections to over 5,000 institutions and over 45 million patient records, licensed to 19 of the top 20 big pharma companies and hundreds of biotechs through multi-year subscriptions. Data margins are stable in the mid-70s range.

Dec 3, 2025, 3:30 PM

Transcript

Tempus AI Discusses Q3 Profitability, Strategic Acquisitions, and Future Growth

TEM

New Projects/Investments

M&A

Revenue Acceleration/Inflection

Tempus AI achieved its first positive Adjusted EBITDA in Q3, a long-term goal, and plans to reinvest two-thirds of incremental growth profit dollars back into the business over the next three years, with one-third dropping to Adjusted EBITDA.
The company closed the Ambry acquisition in February this year, strategically expanding into hereditary screening, rare and undiagnosed disorders, and gaining a more longitudinal patient data perspective, noting that Ambry was already EBITDA positive.
Tempus AI signed a $200 million data license deal with AstraZeneca and Pathos AI this year, which will be largely recognized ratably over the next three years, building on a prior $320 million deal with AstraZeneca in 2021.
The xT solid tumor DNA test received FDA approval and ADLT status, resulting in a $4,500 Medicare price point (up from approximately $3,000 for the non-ADLT version). By the end of Q3, 30% of solid tumor DNA testing volume had migrated to xT, with plans to migrate the vast majority of the remaining 70% in 2026.
Key upcoming product milestones include submitting the xF liquid biopsy test to the FDA and awaiting reimbursement for the xM tumor naive MRD test.

Dec 3, 2025, 3:30 PM

Transcript

Tempus AI Discusses Q3 Adjusted EBITDA, Strategic Deals, and Future Growth

TEM

Guidance Update

Product Launch

M&A

Tempus AI achieved its first positive Adjusted EBITDA in Q3. The company plans to reinvest two-thirds of incremental growth profit dollars back into the business and allow one-third to drop down to Adjusted EBITDA over the next three years, assuming 25% annual top-line growth.
A $200 million data license deal with AstraZeneca and Pathos AI will be recognized ratably over the next three years.
The xT CDx solid tumor DNA test, with FDA approval and ADLT status, carries a $4,500 Medicare reimbursement rate. By the end of Q3, 30% of solid tumor DNA testing volume had migrated to this version, with plans to migrate the majority of the remaining 70% in 2026.
The acquisition of Ambry, closed in February 2025, was strategic for expanding into earlier cancer journey interactions and rare/undiagnosed disorders, and Ambry was already EBITDA positive.

Dec 3, 2025, 3:30 PM

Transcript

Tempus AI Reports Strong Q3 2025 Growth and Positive Adjusted EBITDA

TEM

Revenue Acceleration/Inflection

New Projects/Investments

Guidance Update

Tempus AI reported strong Q3 2025 organic growth of 28%, with oncology volumes accelerating to 27% and Ambry Genetics growing 33%. The company also achieved positive adjusted EBITDA.
The data licensing business demonstrated robust performance, growing 37% in the quarter , with over $150 million in new contracts signed after Q2 and a 140% net revenue retention in 2024.
Tempus AI anticipates favorable long-term reimbursement trends, targeting 40% of xT volumes at ADLT pricing by year-end and aiming for 85% by the end of 2026. The company plans to submit its larger liquid biopsy panel to the FDA soon, expecting it to be a catalyst in 2027.
The company's strategy involves reinvesting two-thirds of incremental gross profit back into the business over the next three years to sustain a 25-30% long-term growth rate, rather than maximizing short-term adjusted EBITDA.

Nov 13, 2025, 3:00 PM

Transcript

Earnings Transcripts

Quarterly earnings call transcripts for Tempus AI.

Q3 2025

Nov 4, 2025

→

Q2 2025

Aug 8, 2025

→

Q1 2025

May 6, 2025

→

View All Transcripts

Ask Fintool AI Agent

Get instant answers from SEC filings, earnings calls & more

What did Eric Lefkofsky say about margins?What are Tempus AI's strategic priorities?How is Tempus AI positioned vs competitors?How did Tempus AI do last quarter?

Tempus AI (TEM)

Analyst Earnings Quarterly Reports

Q4 2024

Q3 2024

Q2 2024

Executives

Eric Lefkofsky

Andrew Polovin

Erik Phelps

James Rogers

Ryan Fukushima

Board Members

David Epstein

Eric Belcher

Jennifer Doudna

Nadja West

Peter Barris

Scott Gottlieb

Theodore Leonsis

Wayne A.I. Frederick

Analyst Coverage

Daniel Brennan

Michael Ryskin

Ryan MacDonald

David Westenberg

Mark Massaro

Andrew Brackmann

Dan Arias

Mark Schappel

Tejas Savant

Casey Woodring

Daniel Arias

Rachel Vatnsdal

Rachel Vatnsdal Olson

Ricky

Subhalaxmi Nambi

Colleen

Colleen Babington

Douglas Schenkel

Doug Schenkel

Mark [indiscernible]

Ryan McDowell

Subbu Nambi

Yuko Oku

Latest news

Earnings Transcripts

Q3 2025

Q2 2025

Q1 2025

Ask Fintool AI Agent